Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.

Abstract: This invention is directed to a process for making a salt of a carboxylic acid. The process comprises contacting a catalyst with an alkaline mixture comprising a primary alcohol. In one embodiment, for example, the catalyst comprises a metal support (preferably a metal sponge support) having a copper-containing active phase at the surface thereof. The support is resistant to deformation under the conditions of the dehydrogenation reaction. In another embodiment, the catalyst comprises a metal sponge having a copper-containing active phase at the surface thereof and a supporting structure containing at least 10% non-copper metal. This invention is also directed to copper-containing catalysts which may, for example, be used in the above process. This invention is further directed to processes for making such catalysts.

Abstract: The present invention provides a method for detecting fluorescence by using a solid support to which a probe molecule to be detected is fixed, wherein background is reduced by using a quenching agent. By using present invention, detection sensitivity of a DNA chip can be increased and stable data can be obtained.

Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.

Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.

Abstract: This application relates to isotopically labeled affinity markers of the formula (II) for mass spectrometric analysis of proteins. In formula (II), the groups A, PRG, S, Z, L', Z', R, R', k, l, m, and n are as defined in the claims. The application also provides a process for preparing these materials, a method for analyzing proteins using such materials, and a kit containing one or more of these materials.

Abstract: A method to prepare new or unexpected polymorphs of materials which have not been observed, or to obtain a known polymorph under different conditions than those in which it is usually made, by using a laser to cause nucleation and crystal growth to occur in a supersaturated solution in such a way as to obtain a crystal structure which would not normally appear without the use of the laser.

Abstract: An aqueous high-concentration solution of N,N-dialkylglycine, economical, easy to handle, and useful for subsequent organic chemical reactions, is provided. Also is provided a process for production thereof. The aqueous high-concentration solution of N,N-dialkylglycine which contains the N,N-dialkylglycine at a concentration of 30–80% by mass, and a metal-mineral acid salt at a content of 0.3–3% by mass can be produced industrially from an aqueous N,N-dialkylglycine alkali metal salt as the source material by the steps of (i) neutralizing an aqueous solution of an N,N-dialkylglycine alkali metal salt with a mineral acid, (ii) condensing the obtained aqueous solution by removal of water, and (iii) separating by solid-liquid separation the deposited alkali metal-mineral acid salt from the resulting slurry of the aqueous N,N-dialkylglycine solution and the alkali metal-mineral acid salt.

Abstract: A process for preparing Anhydrous Betaine and Betaine Hydrochloride comprises treating a chloroacetic acid with sodium carbonate, and then dropping liquid trimethylamine to obtain Betaine products, wherein ion exchange resin and decompression process are utilized to assure the product having high purity and yield rate.

Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

Abstract: Site-specific isotopically-labeled valine, leucine, and isoleucine and biosynthetic precursors for these amino acids are provided. The amino acids are labeled with 13C or 14C at the methyl group carbon atom(s) most remote from the carboxyl group. Also disclosed are the biochemical precursors of these labeled amino acids, 2-keto-4-(nC)butyric acid and 2-keto-3-(nC-methyl)-4-(nC)-butyric acid in which n, at each occurrence, is 13 or 14. Also disclosed are proteins, protein fragments, and polypeptides containing these site-specifically isotopically labeled amino acids, and methods for preparing the biochemical precursors, the amino acids, and the proteins, protein fragments, and polypeptides.

Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.

Abstract: A process for preparing N,N-Dimethyl Glycine Hydrochloride, comprises treating a chloroacetic acid with aqueous dimethylamine, and then dropping by hydrochloric acid to obtain N,N-dimethyl glycine as well as its hydrochloride salt, wherein decompression process is utilized to assure the product purity and active carbon is employed for cost saving aspect.

Abstract: A method for producing D-allo-isoleucine is provided. The method comprises converting L-isoleucine to the corresponding hydantoin. A mixture containing the hydantoin is contacted with a D-hydantoinase to stereoselectively hydrolyze any D-allo-isoleucine hydantoin in the mixture to the corresponding N-carbamoyl-D-allo-isoleucine. The N-carbamoyl-D-allo-isoleucine is decarbamoylated to produce D-allo-isoleucine. Preferably the contacting of the hydantoin with a D-hydantoinase is carried out under conditions permitting the simultaneous epimerization of the chiral center at C-5 of the hydantoin.

Abstract: A method to select and prepare polymorphs of materials by switching the polarization state of light employing non-photochemical laser-induced nucleation.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such resins may be used in dental restorative materials to help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.

Abstract: The present invention provides a method for enantioselectively reducing a prochiral carbon centered radical having one or more electron donator groups attached directly to the central prochiral carbon atom of the radical, and/or attached to a carbon atom within 1 to 4 atoms of the central prochiral carbon atom, comprising treating said radical with a chiral non-racemic organotin hydride in the presence of a Lewis acid.

Abstract: The invention relates to a process for preparing betaines of formula (I) wherein R1 represents a C1-C24 hydrocarbon group, and R2 and R3 independently represent a C1-C3 hydrocarbon group, comprising reacting an aqueous solution of an ethoxylated quaternay ammonium compound of formula (II) wherein R1, R2, and R3 have the same meaning as described above and X− represents a suitable anion, with oxygen or an oxygen-containing gas under alkaline conditions in the presence of a supported and promoted Pt catalyst at a temperature ranging from room temperature to 70° C. Preferably, use is made of a Pt/Bi/C catalyst.

Abstract: &agr;,&bgr;-Unsaturated amides and esters are converted to &agr;,&bgr;-substituted amino amides, esters, and acids. An &agr;,&bgr;unsaturated amide or ester is first converted to an &agr;,&bgr;-hydroxysulfonamide or hydroxycarbamate amide or ester using an osmium-catalyzed aminohydroxylation. The &agr;,&bgr;-hydroxysulfonamide or hydroxycarbamate amides or esters is then cyclodehydrated to produce a &agr;,&bgr;-N-sulfonyl- or the &agr;,&bgr;-N-carbamoylaziridine amide or ester. The ring of aziridine intermediate is then nucleophilically opened in a regioselective manner with a variety of nucleophiles to give the $g(&agr;,&bgr;-substituted amino- amides or esters. Preferred nucleophiles include sulfur, oxygen, carbon, and nitrogen nucleophiles.

Abstract: Processes for preparing N-methyl-L-alanine derivatives and novel intermediates of the process. The derivatives and intermediates are useful for preparing cell-binding agent/maytansinoid complexes.

Abstract: The invention relates to new compounds containing 1-8 active groups of the type 3,3,6,6-polysubstituted 2-morpholinone and having the formula F (A′—Z)m—X  (F), wherein m is a number from 1 to 8; X is an organic anchor group of valency m and in case that m is not 1, X may also be a direct bond, SO2, P or PO; A′ is a monovalent group of the formula E  containing one linking group; Z is a direct bond, —O—, —S—, —SO—, —SO2— or —NR′14—; provided that Z is —O—, —S—, —SO—, —SO2— or —NR′14— if m is 1 and the linking group in formula E is G3 or G5; G1 is hydrogen; C1-C18alkyl; C2-C18alkyl substituted by OH and/or phenyl; oxyl; OH; C2-C12cyanoalkyl; C2-C12cyanoalkoxy; C1-C18alkoxy; C5-C12cycloalkoxy; C3-C8alkenyl; C3-C8alkynyl; C3-C8alkenyloxy; C7-C12phenylalkyl; C7-C12phenylalkyl substituted by hydroxy, C1-C4alkyl and/or C1-C4

Abstract: There are provided cosmetics which have not only a reduced effect on the “gleam” caused by irregular light reflection but also a reduced effect on “stickiness” based on an oil raw material, giving a good feeling during use such as spreadability, etc., and being excellent in the sustaining of the makeup effect. There are used N&egr;-long chain acyllysine crystals whose average diameter or mode diameter lies in the range of 3˜15 &mgr;m without being subjected to the mechanical pulverization.

Abstract: An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) and compounds of the formula (VI) can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

Abstract: Compounds of formula (I) wherein R is an alkyl, aryl or arylalkyl group wherein the aryl is phenyl naphthyl or heterocycle; R1 and R2, the same or different, are hydrogen atoms or alkyl groups; R3 is an aryl or arylalkyl group wherein the aryl is as above; R4 is a heterocycle optionally substituted with a heterocycle or phenyl, or it is a phenyl group substituted with a heterocycle (R4 is not imidazole or indole); X is a bond or —OCONH or —CONH— group, processes for their preparation and pharmaceutical compositions thereof, are described. The compounds of formula (I) are endowed with a dual ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular disease.

Abstract: 6-tert-Butyl-1,1-dimethylindane derivatives which are unsaturated in the 4-position of formula: X represents: (i) either a radical of formula: (a)  and Y represents a radical of formula: (b) (ii) or a radical of formula: (c)  and Y represents either a radical of formula (b) or a radical of formula: Z being —O—, —S— or R1 represents —CH3, —(CH2)p—OR4, —(CH2)p—COR5 or —S(O)t—R6, p being 0, 1, 2 or 3, t being 0, 1 or 2, R2 represents H or lower alkyl, R3 represents H, lower alkyl or —COR7, R4 represents H, lower alkyl, —COR7, aryl, aralkyl, mono- or polyhydroxyalkyl, or a polyether radical, R5 represents H, lower alkyl, —OR8 or —N(r′)(r″), R6 represents H or lower alkyl, R7 represents lower alkyl, R8 represents H, alkyl, alkenyl, alkynyl, aryl, aralkyl, mono- or polyhydroxyalkyl, a sugar residu

Abstract: Peptoid compounds of Formula I and Formula II are disclosed The compounds are useful in the treatment of matrix metalloproteinase-mediated disorders.

Abstract: The invention relates to the use of certain acid donors as stabilizers in pharmaceutical compositions, and to the stabilized pharmaceutical compositions resulting therefrom.

Abstract: A 2- or 4-nitrobenzenesulfonamide is allowed to react with an alkali metal alkoxide to remove a nitrobenzenesulfonyl group to thereby obtain an amine corresponding to the amide. Furthermore, a method for producing an amine derivative by allowing the resulting amine without isolation to react with an activated, substituted oxycarbonyl compound or an activated acyl compound is provided. According to this method, a corresponding free amine and its substituted derivative can be produced easily and industrially advantageously from the 2- or 4-nitrobenzenesulfonamide without using a thiol compound.

Abstract: A method to prepare new or unexpected polymorphs of materials which have not been observed, or to obtain a known polymorph under different conditions than those in which it is usually made, by using a laser to cause nucleation and crystal growth to occur in a supersaturated solution in such a way as to obtain a crystal structure which would not normally appear without the use of the laser.

Abstract: It has been discovered that compounds of the formula: and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined below, are more readily absorbed and more bioavailable than the corresponding carboxylic acids from which they are derived, both of which are effective inhibitors of the binding of VCAM-1 to VLA-4 in vivo and are useful in treating inflammation in inflammatory diseases in which such binding acts to bring on the inflammation.

Abstract: The invention concerns a method for preparing methionine aminoamide. The invention also concerns the preparation of methionine without co-production of salts, from an aqueous solution containing essentially methionine aminonitrile by producing during a first step aminoamide followed by two complementary steps.

Abstract: Compounds of the formula I as defined, and their pharmaceutically acceptable salts are VLA-4 antagonists which are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of inflammatory and autoimmune diseases, particularly inflammatory airways diseases. They are particularly useful in reducing post-surgical inflammation, especially that resulting from transplant surgery.

Abstract: A compound of formula wherein the substituents are defined as in the specification and salts or hydrates thereof is disclosed as well as a method of treating disorders associated with the inactivation or excessive degradation of cholecystokinin.

Abstract: The present invention relates to an environmentally acceptable method of producing glycine betaine esters that produces no toxic by-products during the synthesis. The method produces only product, recyclable material for reuse in the process, and recovered material which can be sold for uses, such as fertilizer.

Abstract: The present invention provides a method and composition for treating or preventing pathogenic effects in a mammal caused by intracellular calcium overload, comprising administering to a mammal a mixture of sodium co-transport dependent amino carboxylic acids or their physiologically acceptable salts in an amount sufficient to substantially saturate sodium-dependent amino carboxylic acid transport mechanisms of a cell's plasma membranes. Administration of these amino carboxylic acids can advantageously treat or prevent cell lysis and irreversible cell damage caused by intracellular calcium overload, especially in mammals suffering from a disease condition associated with or resulting from insufficient tissue oxygenation.

Abstract: This invention is directed to a process for making a salt of a carboxylic acid. The process comprises contacting a catalyst with an alkaline mixture comprising a primary alcohol. In one embodiment, for example, the catalyst comprises a metal support (preferably a metal sponge support) coated with copper. The support comprises at least about 10% (by weight) non-copper metal, and the copper-containing coating comprises from about 0.005 to about 0.5 grams of copper (per gram of said metal support). In another embodiment, the catalyst comprises a metal support (preferably a metal sponge support) coated with silver. The support comprises at least about 10% (by weight) non-silver metal, and the silver-containing coating comprises from about 0.005 to about 0.5 grams of copper (per gram of said metal support). In another embodiment, the catalyst comprises at least about 15% (by weight) non-copper metal, and at least about 10% (by weight) copper.

Abstract: New fluorinated derivatives useful as surfactants or in the transport of drug or markers, or in drug targeting, and preparations containing the derivatives, for medical, cosmetic and veterinary uses, having the formula: wherein RF is a fluorinated radical, X is a linear or branched alkylene, R1 is H or CH3, R2 is a radical having at least one OH group, R3 is a radical derived from an amino acid or a peptide, 1≦n≦50 and 0≦m≦200 with 0.2≦n/n+m≦1. These derivatives can be used as prodrugs or in formulating pharmaceutical, cosmetic and veterinary preparations, in biology and medicine, notably in compositions acting as carriers of oxygen and other gases, of contrast agents, or as carriers of substances used in therapy, or as carriers of markers.

Abstract: Osmium-catalyzed aminohydroxylation reactions are accelerated and expanded in scope by the use of olefinic substrates having ionic groups, either anionic or cationic. The use of ionic groups on olefinic substrates also extends the aminohydroxylatable positions of unsaturations to include &agr;,&bgr;, &bgr;,&ggr;, and &ggr;,&dgr; positions, with respect to such ionic groups. A mechanism for the disclosed acceleration and extension is provided.

Abstract: New fluorinated derivatives useful as surfactants or in the transport of drug or markers, or in drug targeting, and preparations containing the derivatives, for medical, cosmetic and veterinary uses, having the formula: 1

Abstract: A high purity, water-white, clear, light stable, non-toxic, formaldehyde-free composition for inhibiting growth in a substance requiring microbial inhibition comprising about 40-60% by weight of an aqueous solution of hydroxymethylaminoacetate in the form of its alkali metal salt which is formed by the reaction of a salt of glycine, with formaldehyde, in an aqueous medium, at a pH of about 10.5-12.5, characterized by carrying out the reaction at a molar ratio of glycine to formaldehyde sufficient to maintain a molar excess of glycine in the medium and to leave a predetermined amount of residual glycine present in the composition at the conclusion of the reaction, and to preclude the presence of any detectable free formaldehyde as methylene diol in said composition.

Abstract: Disclosed are a novel process for preparing D-alloisoleucine and an improved process for epimerizing L-isoleucine to prepare D-alloisoleucine. In the former process, (2S, 3S)-tartaric acid derivative of formula I below; wherein R stands for a hydrogen atom, a C1-C3 lower alkyl group, lower alkoxy group, chlorine atom, bromine atom and nitro group; and “n” is a number of 0, 1 and 2; is combined with an epimer mixture of L-isoleucine and D-alloisoleucine in a reaction medium to form a complex of D-alloisoleucine and the compound of formula I. The precipitated complex is decomposed by putting it in an alcohol to isolate D-alloisoleucine. In the latter process, L-isoleucine is suspended in an inert solvent which does not substantially dissolve amino acids, and epimerized in the presence of C1-C5 saturated lower fatty acid and salicylaldehyde.

Abstract: The invention relates to the use of certain acid donors as stabilizers in pharmaceutical compositions, and to the stabilized pharmaceutical compositions resulting there-from.

Abstract: The invention relates to the use of certain acid donors as stabilizers in pharmaceutical compositions, and to the stabilized pharmaceutical compositions resulting therefrom.

Abstract: This invention provides a process for producing a betaine/amine oxide mixture. This process comprises reacting, in a liquid medium, an alkali metal &ohgr;-halocarboxylate with a first tertiary amine of the formula Ra2RbN, wherein each Ra group is a hydrocarbyl group which independently has from 1 to about 4 carbon atoms, and wherein the Rb group is a hydrocarbyl group which has from about 8 to about 24 carbon atoms, to produce a betaine product solution. To the betaine product solution is added a second tertiary amine of the formula Ra2RbN, wherein each Ra group is a hydrocarbyl group which independently has from 1 to about 4 carbon atoms, and wherein the Rb group is a hydrocarbyl group which has from about 8 to about 24 carbon atoms, to produce an amine/betaine mixture. The first and second tertiary amines can be separate portions of the same amine. Preferably, however, the first and second tertiary amines differ from each other.

Abstract: Novel inhibitors of protein farnesyltransferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer, restenosis, atherosclerosis, psoriasis and endometriosis.

Abstract: A novel amino acid derivative represented by the general formula (I) shown below or a salt thereof have now been provided by chemical synthesis, and it has been found that these new compounds stimulate proliferation and physiological activities of the T cells of mammals, have an immunomodulating activity and also have an antitumor activity or a carcinostatic activity. It has also been found that these new compounds have an effect of stimulating the proliferation of hematopoietic stem cells. wherein y is 0 or 1; R1 represents an unsubstituted C1-C8 alkyl group or others; R2 represents a hydrogen atom, a C1-C5 alkyl group or others; R3 represents a hydrogen atom, a C1-C8 alkyl group or others; R4 represents a hydrogen atom, a C1-C3 alkyl group or others; R5 represents a group —OR42, a group  or others.

Abstract: Process for the preparation of N-acetyl protected amino acids of Formula I by amido carbonylation utilizing carbon monoxide, nitrile, and an aldehyde in the presence of a metal catalyst.

Abstract: A heat transfer/cooling fluid for low temperatures containing from about 15% to about 70% of trimethyl glycine or derivatives thereof and from about 30% to about 85% of water. The heat transfer/cooling fluid is environmental-friendly and non-toxic. It has good heat transfer properties and is suitable for, e.g., the needs of the food industry and solar panels.

Abstract: Process for the preparation of an N-acyl amino carboxylic acid by means of a carboxymethylation reaction. In this reaction, a reaction mixture is formed which contains a base pair, carbon monoxide, hydrogen and an aldehyde with the base pair comprising a carbamoyl compound and a carboxymethylation catalyst precursor. In a preferred embodiment, the carbamoyl compound and aldehyde are selected to yield an N-acyl amino carboxylic acid which is readily converted to N-(phosphonomethyl)glycine, or a salt or ester thereof.

Abstract: The present invention is relative to a chemical method of producing compounds of the general formula (I) ##STR1## starting from compounds of the general formula (II) and (III) ##STR2## under radical conditions. Products I are used as intermediates in the synthesis of bioactive substances.